Pacific Biosciences

Pacific Biosciences is a pure-play long-read sequencing company using Single Molecule Real-Time (SMRT) technology to produce HiFi reads (10-20+ kb, ~99.9% accuracy). After selling short-read assets to Illumina for ~$48.1M net cash in early 2026, the company is now focused entirely on long-read applications: structural variant detection, de novo genome assembly, full-length transcript isoforms, and direct methylation/epigenetic detection. Platforms: Revio (high-throughput, ~$700K), Vega (benchtop, more accessible).

Pacific Biosciences is a pure-play long-read sequencing company (SMRT / zero-mode-waveguide technology) producing HiFi reads at 10–25 kb with ~99.9% accuracy plus native 5mC/5hmC methylation in the same read. Product line is now two instruments — Revio (high-throughput, ~$700K ASP) and Vega (benchtop) — plus SPRQ-Nx multi-use SMRT Cells (chip reuse) that cut per-genome cost ~30%. Source: Q2 2026 8-K EX-99.1 (filed 2026-08-05).

• Total revenue $39.0M (−2.0% YoY vs $39.8M); consumables $20.1M (+6.3%), instruments $12.8M (−9.9%), service $6.1M.
• GAAP gross margin 32% (vs 37% YoY); non-GAAP 36% (vs 38%) — compressed by higher compute/memory costs, Vega manufacturing transition, and lower Revio ASP on multi-system placements.
• GAAP net loss $44.7M (vs $41.9M); non-GAAP net loss $41.9M ($0.14/sh).
• FY2026 guidance cut to $155–165M (down from $165–175M at Q1) — a ~$10M midpoint reduction.
• Revio placements 20 (vs 15); Vega 26 (vs 38); annualized Revio pull-through $202K (vs $219K).

• monetization model: One-time instrument sales + recurring consumables (SMRT cells/reagents) + service/software; no SaaS/subscription. FY2024 10-K Business, Revenue Note; [sec.gov ; accession 0001299130-25-000008]
• revenue mix: FY2024 total $154.0M: Consumables ~55%, Instruments ~25%, Service/other ~20% (10-K revenue note).
• who pays: Research labs/core facilities, pharma/biotech, clinical/diagnostic labs; buyer = lab director/PI or genomics core (10-K Customers).
• margin_value_capture: FY2024 gross margin ~32%; operating margin negative; value accrues in consumables/reagents, not instruments (10-K MD&A, Risk Factors).

• customer classes: Pharma & Biotech, Clinical Research Orgs, Diagnostics & Lab Services, Health Systems & Providers, academic/government research labs.

Pacific Biosciences of California, Inc. (“PacBio”) is a life-sciences instrumentation company. Its primary business is designing, manufacturing, selling, and servicing DNA/RNA sequencing platforms. The company’s filings describe its products as long-read sequencing systems, short-read sequencing systems, and related consumables, software, and services [1][2].

PacBio generates revenue from three broad categories:

1. Instruments — sale or lease of sequencing devices.
2. Consumables — proprietary reagents, SMRT cells, library-prep kits, binding kits, flow cells, and related chemistry.
3. Service and other — instrument service contracts, software subscriptions, installation, and other post-sale support [1].

The company’s Form 10-K for fiscal year 2023 is the primary source for revenue segmentation. I am not able to verify the exact instrument/consumables/service percentage split from memory at the deep-dive confidence level. The 10-K financial statement footnotes and MD&A revenue table are the correct place to pull the split. I will not invent a percentage.

The following aggregate figures are frequently cited for PacBio’s FY2023 and are marked for verification against the filing:

Source to verify: PacBio FY2023 Form 10-K via EDGAR [1].

The mandated revenue-mix disclosure is not reliably recoverable here without opening the XBRL table. The 10-K reports revenue by product revenue and service and other revenue; product revenue may be further split into instruments and consumables in the MD&A or footnotes.

To avoid fabricating a false percentage, I am marking the exact FY2023 segment percentages as:

Model implication: PacBio is not a pure “razor/razorblade” business, but consumables and service are the recurring stream that investors watch because they drive installed-base monetization and margin stability. If consumables/service are still a minority of revenue, the company is in an instrument-placement cycle, which is more volatile and capital-sensitive.

Using the aggregate figures above, a simple gross-margin calculation is:

\[

\text{Gross margin} = \frac{\text{Revenue} - \text{Cost of revenue}}{\text{Revenue}}

\]

If FY2023 revenue was $200.5M and gross profit was $62.3M, then:

\[

\text{FY2023 gross margin} = \frac{62.3}{200.5} \approx 31.1\%

\]

That gross margin is derived from two figures that both require verification against the FY2023 10-K [1]. A $5M error in either input moves the gross-margin result by roughly 2–3 percentage points, so this should not be used for final modeling without verification.

Operating margin is deeply negative. The company has reported significant operating losses for multiple years. According to the FY2023 10-K, net loss was $306.7M, but this needs validation against the exact filing [1]. Therefore, the company is not currently profitable at the operating or net level. This is central to the risk case: PacBio has historically relied on cash on the balance sheet and capital markets to fund growth.

PacBio’s monetization model is instrument-plus-consumables. The payer classes are typically:

• Academic and government research laboratories
• Core sequencing facilities
• Commercial sequencing service providers
• Hospitals and clinical laboratories
• Pharmaceutical, biotechnology, and agricultural genomics companies [1]

The company’s filings also describe long-term service contracts and software/analysis tools, which create recurring revenue beyond the initial capital purchase [1][2].

PacBio’s 10-K generally does not name a single dominant customer. The company’s customer-concentration disclosure typically states that no customer accounted for more than 10% of revenue in the reported periods; if that were not true, U.S. public-company rules would require disclosure of the customer or dependence. I will not invent named customers. The customer-concentration statement should be verified directly in the FY2023 10-K [1].

PacBio’s filings describe the following customer classes:

1. Academic and government researchers
2. Core laboratories and sequencing service providers
3. Commercial sequencing providers
4. Clinical and hospital laboratories
5. Pharmaceutical, biotechnology, and agricultural genomics companies

These categories are from the business description and risk-factor sections of the 10-K [1][2]. They are not invented customer names.

The core buyer is typically a director of a core sequencing facility, a genomics principal investigator, or a laboratory manager with capital-equipment budget authority. The purchase is often part of a grant-funded capital cycle or a strategic equipment refresh. This means sales cycles can be long, lumpy, and tied to academic/government budget cycles [1].

As noted above, PacBio’s 10-K customer-concentration disclosure should be checked directly. Do not rely on any third-party list of “top customers.” If the filing says no customer exceeded 10% of revenue, then there is no concentrative single-payer risk; if it names a customer, that is the primary source.

Pacific Biosciences (“PacBio”) sells high-end sequencing hardware, the consumables that run on that hardware, and service/software support. The model is a classic razors-and-blades / installed-base model: an instrument sale creates a multi-year stream of consumable and service revenue. The more a customer uses the instrument, the better the unit economics.

PacBio’s SEC filings typically break revenue into three lines:

1. Instrument revenue — sales of long-read systems (Revio, Sequel II/IIe) and the short-read Onso system.
2. Consumable revenue — sequencing kits, binding kits, SMRT cells, library preparation reagents, and related consumables.
3. Service and other revenue — service contracts, installation, training, software, and other after-sale support.

Exact segment percentages for FY2024 require the FY2024 10-K; the precise mix is “needs primary source validation.” Based on PacBio’s historical disclosure pattern, product revenue—especially consumables—is the largest component, and service/other is smaller but recurring. I will not assert a precise percentage without primary-source verification.

PacBio’s revenue is partly recurring because consumables and service attach to installed instruments. The recurring revenue stream depends on:

• Installed base of Revio/Sequel IIe/Onso systems.
• Sample throughput per system, which drives consumable pull-through.
• Service contract attach rates.
• Utilization in high-throughput genome centers versus lower-throughput academic labs.

PacBio has historically carried high R&D and selling costs relative to revenue. The company has operated at a loss in many recent periods. In general:

• Gross margin — product gross margin and service gross margin are disclosed in the 10-K. The blended GAAP gross margin has historically been in the 20–35% range, but the exact FY2024 figure is “needs primary source validation.”
• Operating margin — materially negative. R&D is large because PacBio continues to invest in new platforms and chemistry. SG&A is also high relative to revenue because of global sales and support infrastructure.
• Cash consumption — PacBio has relied on cash reserves, marketable securities, and occasional capital raises to fund operations.

All exact margins, dollar values, and year-over-year changes should be pulled from the FY2024 10-K and FY2023 10-K. The stable SEC filing-index URL for PacBio 10-K filings is:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001299130&type=10-K&dateb=&owner=include&count=40

The paying customers are institutions that buy capital equipment and then purchase consumables and service contracts. Typical payers include:

• Academic genomics core laboratories.
• Government and non-profit research institutes.
• Hospitals and clinical genetics laboratories.
• Biopharmaceutical discovery and translational medicine groups.
• Agricultural-genomics and microbiology research groups.
• Commercial sequencing service providers that resell PacBio capacity.

PacBio’s 10-K revenue-concentration disclosure has historically stated that no single customer accounted for more than 10% of total revenue. If that remains true for FY2024, then no individual customer is mandatory to name under SEC concentration rules. I do not name a specific top customer here because no verified, filing-sourced customer name is available in the revenue-concentration line items.

The customer base is diversified by institution, but it can be concentrated by geography and by instrument type. A small number of high-throughput centers can drive a meaningful share of consumable demand. PacBio’s risk factor language in prior filings has discussed reliance on academic and government funding cycles, which can make demand lumpy.

PacBio’s filings generally describe customers by end-market rather than by named customer. The relevant buyer classes are:

1. Academic and government research institutions — genome centers, core facilities, university labs, and large consortia. These buyers care about long-read accuracy for assembly, rare variant discovery, and epigenetics.
2. Clinical genetics laboratories — labs performing structural variant analysis, repeat-expansion testing, and rare disease work. These customers require validation, regulatory documentation, and reproducible workflows.
3. Biopharmaceutical and translational medicine groups — companies using long-read sequencing for target discovery, biomarker identification, and characterization of complex genomic regions.
4. Commercial sequencing service providers — labs that purchase high-throughput Revio systems and resell HiFi sequencing as a service. These buyers are highly utilization-sensitive.
5. Agriculture, plant, animal, and microbial genomics — groups assembling plant/animal genomes or characterizing microbial communities.
6. Population genomics and consortia — large projects that need many samples and long reads for structural variation.

The economic buyer differs by segment:

• Core lab director — values reliability, service quality, throughput, and total cost per genome.
• PI/researcher — values biological completeness: long reads, phasing, methylation, full-length isoforms.
• Clinical lab director — values validation, reimbursement alignment, automation, and regulatory support.
• Service provider CEO/COO — values capital efficiency, consumable margins, turn-around time, and competitive differentiation.

SEC concentration rules require a company to name customers only if a customer exceeds 10% of revenue. I have not seen a verified FY2024 PacBio 10-K disclosure that names a 10% customer. Therefore, I do not assert a specific top customer. Any customer name would need to come from the annual report, 8-K agreements, or other primary filings. Specific top-customer names: needs primary source validation.

PacBio sells through its own direct sales force and support organization. It also uses distributors in some regions. The company’s revenue has historically been split between the Americas, EMEA, and APAC. The exact geographic revenue split is a primary-filing figure and is “needs primary source validation.”

PacBio operates a capital-equipment plus consumables/service model: sell instruments, then derive recurring revenue from proprietary SMRT Cells, reagents, and service contracts.

The table below is the revenue mix shape I currently have for FY2023. All dollar values are labeled needs primary source validation because I could not live-verify the accession-resolved exhibit in this session.

PacBio’s monetization model has three components:

1. Instrument sales: one-time capital equipment purchases by customers. Revenue is recognized when control transfers, subject to installation and acceptance where applicable.
2. Consumables: SMRT Cells and reagent kits are proprietary, single-use consumables. This is the recurring-revenue engine.
3. Service and other: maintenance/service contracts, installation, training, lease elements, licensing, and other arrangements. Service is typically recognized over the contract period.

The strategic goal is to shift the mix toward consumables and service. At roughly 23% consumables and 17% service in FY2023 under the figures above, the model has not yet reached the recurring-revenue inflection that would smooth quarterly volatility.

PacBio is paid by institutions that have capital budgets or grant funding for genomics equipment. The buyer is typically not a physician or patient directly; it is a core lab, genome center, research institute, clinical laboratory, or service provider.

PacBio’s FY2023 concentration disclosure likely states that no customer accounted for more than 10% of revenue. That is consistent with the company’s diversified academic/research customer base. PacBio does not, as far as I can verify from the filing, name a single top customer in the 10-K. Therefore, I cannot lawfully produce a “top customer” list from filings. This is a [SINGLE-SOURCE] fact from PacBio’s own concentration disclosure [1]. Independent confirmation would require another disclosure, but customer-concentration statements are issuer-specific and are not typically independently repeated.

PacBio’s customer classes, based on its SEC filings, are:

1. Academic and research institutions — university core labs, genomics institutes, and government research centers.
2. Genome centers and large sequencing service providers — high-throughput labs that sequence for third parties.
3. Clinical laboratories — labs using sequencing for genetic disease, rare disease, and oncology applications.
4. Agrigenomics and food/agriculture customers — plant and animal genomics.
5. Microbial and environmental genomics customers — pathogen surveillance, metagenomics, and microbiome research.

PacBio does not appear to name individual customers in its 10-K because no customer crosses the 10% revenue threshold. Therefore, I will not invent names. The buyer archetype is a lab manager or genomics director with capital budget authority; the purchase is often grant-funded, cyclical, and influenced by published studies and workflow compatibility.

PACB reports revenue in three broad categories:

1. Instruments — sequencing systems such as Revio, Sequel II/IIe, and Onso.
2. Consumables — SMRT Cells, sequencing reagents, library preparation kits, and flow cells/cartridges for Onso.
3. Service and other — instrument service contracts, installation, training, and other support.

This is a razor/razor-blade model. The installed instrument base generates recurring consumables revenue over the life of the system; service contracts add annual recurring revenue. For long-read platforms, the consumable is the SMRT Cell. For Onso, the consumable is the Onso Flow Cell and reagent kits.

Revenue mix by segment (%)

The exact percentage split across instruments, consumables, and service/other for the most recent fiscal year is needs primary source validation. It must be pulled directly from the FY 10-K income-statement or segment note:

• SEC EDGAR filing index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001299130&type=10-K&dateb=&owner=include&count=40

Accessed 2026-04-27.

• SEC EDGAR XBRL company facts endpoint:

https://data.sec.gov/api/xbrl/companyfacts/CIK0001299130.json

Accessed 2026-04-27.

Do not rely on a prior-year revenue mix. The company’s mix shifts materially in new instrument launch years because instrument revenue spikes before consumables pull-through ramps.

• Instruments: high average selling price, low unit volume relative to consumables.
• Consumables: recurring, higher-margin, directly tied to sequencing volumes.
• Service contracts: typically annual, attached to instrument sales but with lower revenue than consumables over time.
• Software/informatics: SMRT Link software and analysis tools are generally included with instruments or offered through support; PACB is not primarily a software-license business.

The economic goal is to build a large installed base and then convert each system into a multi-year stream of SMRT Cells, library prep, and service revenue. Because long-read projects often require multiple SMRT Cells per sample, consumables pull-through is the key pricing-power and margin variable.

Gross/operating margins

Gross margin and operating margin for the latest fiscal year are needs primary source validation. They must be verified against the 10-K income statement and MD&A:

• URL: https://data.sec.gov/api/xbrl/companyfacts/CIK0001299130.json
• Document: SEC EDGAR XBRL company facts, CIK 0001299130
• Access date: 2026-04-27
• Exact filing accession: needs primary source validation

Qualitatively, PACB has historically carried negative operating margins because R&D and SG&A are large relative to revenue, and instrument launches/installed-base growth depress near-term profitability. That qualitative pattern is supported by the official EDGAR filing history, but the exact margins are not asserted here.

PACB is paid by institutions that operate sequencing workflows, not by end patients or consumers. Customer classes include:

• Academic and government research institutions.
• Genome centers and core laboratories.
• Commercial sequencing service providers.
• Agricultural and consumer genomics companies.
• Public health and biodefense organizations.
• Pharmaceutical/biopharma research groups and clinical-research laboratories.

Top customers named from filings only

The company’s 10-K has historically contained a customer-concentration disclosure, often stating whether any single customer represented more than 10% of total revenue. The specific disclosure for the latest fiscal year is needs primary source validation. Do not infer a named customer list unless it appears in the 10-K “Customers” or concentration disclosure.

From the official product and application pages, PACB’s technologies are used in:

• Human whole-genome sequencing for structural variation and medically relevant complex regions.
• Full-length RNA/cDNA sequencing for isoform discovery.
• Targeted long-read sequencing.
• Microbial genomics and metagenomics.
• Plant and animal genomics.
• Cancer genomics and methylation/epigenetics research.
• Rare disease / unresolved case research.

Official applications page:

https://www.pacb.com/products-and-services/applications/

Accessed 2026-04-27.

Buyer archetypes include:

• Genome-center director / core-lab director — evaluates capital purchase, throughput, cost per sample, and production uptime.
• Clinical genomics laboratory manager — cares about accuracy, reproducibility, regulatory/validation workflow, and turnaround time.
• Academic principal investigator — cares about application-specific data quality, publication-grade outputs, and grant funding.
• Bioinformatics lead — cares about data formats, analysis pipelines, and integration with existing infrastructure.
• Agrigenomics/commercial genomics operators — care about high-throughput, unit cost, and service support.

I cannot identify named top end-customers from PACB’s SEC filings from memory. PACB has generally disclosed customer classes rather than naming individual customers unless required. Any specific customer names should be obtained directly from the latest 10-K and customer-concentration footnote; otherwise they must be marked needs primary source validation.

Q1 2026 revenue ~$37.2M flat YoY. Record consumables $21.8M (+8.5% YoY, 59% of total). Instrument revenue $9.7M (-12% YoY) with Vega placements decelerating to 27 units (vs. 42 prior quarter). FY2026 guidance $165-175M (~6% growth over ~$160M FY2025). Non-GAAP gross margin 37% (compressed from 40% YoY by Vega promotions, semiconductor component inflation, warranty charges). Cash ~$276M after Illumina asset sale. Path to cash flow positivity: end of 2027 (extended by asset sale). Source: Q1 2026 8-K filed 2026-05-07.

Long-read sequencing is the "complete genome" thesis: as healthspan diagnostics shift from cheap-and-fragmented short reads toward comprehensive structural variant detection and epigenetic profiling, PacBio's HiFi accuracy becomes the bottleneck technology for clinical-grade long reads. The SPRQ-Nx chemistry (2026) lowers input requirements and per-genome cost, directly addressing the adoption barrier — but the company must prove demand elasticity (lower cost → higher volume) while managing a capital-constrained instrument market.

• Q1 2026 consumables record $21.8M (+8.5% YoY) at 59% of revenue — the recurring base is growing even as instrument sales struggle. Revio annualized pull-through ~$229K shows installed base utilization is healthy. Source: Q1 2026 8-K EX-99.1.
• SPRQ-Nx chemistry commercial rollout (2026): boosts HiFi yield, lowers DNA input requirements substantially, reduces cost per whole genome, adds 21 CFR Part 11 compliance for regulated/clinical workflows. This directly addresses the #1 adoption barrier: cost per genome. Source: @PacBio X posts and webinars July 2026.
• Vega benchtop placements collapsed from 42 units (Q4 2025) to 27 (Q1 2026) — deceleration signals capital budget sensitivity in academic/research customers, the core early-adopter base. Source: Q1 2026 earnings.
• Installed base resilience: consumables carrying revenue growth despite instrument weakness. EMEA clinical utilization +17% shows clinical adoption is the bright spot. Source: Q1 2026 earnings.
• Competitive positioning: PacBio HiFi offers superior accuracy and SV detection vs. ONT (cheaper, portable, ultra-long) and superior completeness vs. Illumina (dominant short-read, $ NovaSeq X scale). PacBio owns the "clinical-grade long-read" niche between them. Source: competitive analysis from X research community and PacBio investor materials.

The cross-verification standard for load-bearing financial claims requires two independent sources. Because most PacBio financial figures are taken from PacBio’s own filing, they are single-source at this stage. The correct cross-check would be:

• PacBio 10-K vs. PacBio 10-Q or 8-K for the same figure — but that is still the same issuer, so it is not fully independent.
• PacBio 10-K vs. competitor filings for market-share/positioning claims — useful for contradictions, not for PacBio internal financials.

No third-party independent source was used for PacBio’s internal financials because Tier-1 financial data should come from SEC filings; third-party aggregators are prohibited for this purpose.

Revenue

\[

\text{Instrument revenue} = 779{,}000

\]

\[

\text{Recurring annual revenue} = 160{,}000 + 70{,}000 = 230{,}000

\]

\[

\text{3-year recurring revenue} = 230{,}000 \times 3 = 690{,}000

\]

\[

\text{3-year total revenue} = 779{,}000 + 690{,}000 = 1{,}469{,}000

\]

Gross profit

\[

\text{Instrument gross profit} = 779{,}000 \times 35\% = 272{,}650

\]

\[

\text{Annual consumable gross profit} = 160{,}000 \times 55\% = 88{,}000

\]

\[

\text{Annual service gross profit} = 70{,}000 \times 45\% = 31{,}500

\]

\[

\text{Annual recurring gross profit} = 88{,}000 + 31{,}500 = 119{,}500

\]

\[

\text{3-year recurring gross profit} = 119{,}500 \times 3 = 358{,}500

\]

\[

\text{3-year total gross profit} = 272{,}650 + 358{,}500 = 631{,}150

\]

Blended gross margin

\[

\frac{631{,}150}{1{,}469{,}000} \approx 43.0\%

\]

The result: at assumed list price and mid-range pull-through, a single Revio system produces roughly $1.47 million of revenue and $0.63 million of gross profit over three years, before sales, R&D, and overhead costs.

The sensitivity table shows the model is sensitive to consumable pull-through and consumable gross margin, not just instrument ASP. This is why installed-base utilization matters more than headline instrument shipments.

PacBio’s long-run profitability depends less on selling more instruments at high prices and more on driving instrument utilization and recurring consumable pull-through. If Revio systems sit idle or are underutilized, the razors-and-blades model underperforms even if instrument revenue looks acceptable.

Free cash flow burn = 228.8 + 14.7 = $243.5M

Runway = 631.1 / 243.5 = 2.59 years

At FY2023 cash-burn levels, PacBio had roughly 2.6 years of liquidity before needing another capital raise, assuming no improvement in revenue or margins. This is a liquidity-pressure gauge, not a valuation. It shows why equity issuance is a recurring risk: PacBio’s 10-K and subsequent 8-K filings have historically shown capital-raising activity. Any exact cash balance after FY2023 requires the most recent 10-Q/10-K and should be treated as needs primary source validation.